



SHUKRA

PHARMACEUTICALS LTD.

11th November, 2020

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

SUB: - OUTCOME OF BOARD MEETING

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 11th November, 2020 at 04.00 p.m. and concluded at 05:35 p.m.:-

1. Considered, adopted and approved Unaudited Financial Results for the quarter and Half year ended on 30th September, 2020.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited


Arpita Shah
Company Secretary &
Compliance officer

Email id: info@shukrapharmaceuticals.com Website: www.shukrapharmaceuticals.com

CIN : L24231GJ1993PLC019079



SHUKRA

PHARMACEUTICALS LTD.

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30-09-2020

SR NO	PARTICULARS	Standalone					(' in Lakhs)
		Quarter Ended			Half Year		Year Ended
		30-09-2020 (Unaudited) QUARTERLY	30-06-2020 (Unaudited) QUARTERLY	30-09-2019 (Unaudited) QUARTERLY	30-09-2020 (Unaudited) HALF YEARLY	30-09-2019 (Unaudited) HALF YEARLY	31-03-2020 (Audited) YEARLY
1	Income						
	Revenue from operations - Job Charges	167.60	110.89	148.65	278.49	252.99	1,184.60
	Other income	9.91	13.95	140.00	23.86	140.00	0.97
	Total income	177.51	124.84	288.65	302.35	392.99	1,185.57
2	Expenses						
(a)	Cost of materials consumed	7.10	35.21	127.46	42.31	142.68	332.82
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(24.16)	(44.14)	0.00	(68.30)	(8.04)	(25.90)
(d)	Employee benefit expense	90.85	58.02	95.72	148.87	166.89	440.03
(e)	Finance costs	0.30	0.02	-	0.32	0.07	0.21
(f)	Depreciation, depletion and amortisation expense	36.21	36.21	35.49	72.42	50.49	147.82
(f)	Other Expenses	57.99	37.65	27.50	95.64	38.15	283.61
	Total expenses	168.28	122.97	286.17	291.25	390.24	1,178.59
3	Total profit before exceptional items and tax	9.22	1.87	2.48	11.09	2.75	6.98
4	Exceptional items	-	-	-	-	-	10.10
5	Total profit before tax	9.22	1.87	2.48	11.09	2.75	17.08
7	Tax expense	-	-	-	-	-	-
8	Current tax	-	-	-	-	-	13.52
9	Deferred tax	-	-	-	-	-	-
10	Total tax expenses	-	-	-	-	-	13.52
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	-	-	-	-	-	-
12	Net Profit Loss for the period from continuing operations	9.22	1.87	2.48	11.09	2.75	3.56
13	Profit (loss) from discontinued operations before tax	-	-	-	-	-	-
14	Tax expense of discontinued operations	-	-	-	-	-	-
15	Net profit (loss) from discontinued operation after tax	-	-	-	-	-	-
16	Share of profit (loss) of associates and joint ventures accounted for using equity method	-	-	-	-	-	-
17	Total profit (loss) for period	9.22	1.87	2.48	11.09	2.75	3.56
18	Other comprehensive income net of taxes	-	-	-	-	-	-
19	Total Comprehensive Income for the period	9.22	1.87	2.48	11.09	2.75	3.56
20	Total profit or loss, attributable to	9.22	1.87	2.48	11.09	2.75	3.56
	Profit or loss, attributable to owners of parent	-	-	-	-	-	-
	Total profit or loss, attributable to non-controlling interests	-	-	-	-	-	-
21	Total Comprehensive income for the period attributable to	-	-	-	-	-	-
	Comprehensive income for the period attributable to owners of parent	-	-	-	-	-	-
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-	-	-	-	-	-
22	Details of equity share capital						
	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57	156.57
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00	10.00
23	Details of debt securities						
	Paid-up debt capital	-	-	-	-	-	-
	Face value of debt securities	-	-	-	-	-	-
24	Earnings per share						
i	Earnings per equity share for continuing operations						
	Basic earnings (loss) per share from continuing operations	0.59	0.12	0.16	0.71	0.18	0.23
	Diluted earnings (loss) per share from continuing operations	0.59	0.12	0.16	0.71	0.18	0.23
ii	Earnings per equity share for discontinued operations						
	Basic earnings (loss) per share from discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from discontinued operations	-	-	-	-	-	-
ii	Earnings per equity share						
	Basic earnings (loss) per share from continuing and discontinued operations	-	-	-	-	-	-
	Diluted earnings (loss) per share from continuing and discontinued operations	-	-	-	-	-	-
25	Disclosure of notes on financial results						

CIN : L24231GJ1993PLC019079





SHUKRA

PHARMACEUTICALS LTD.

NOTES:

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 11th November, 2020. The statutory auditors have carried out a limited review of the results for the quarter ended September 30, 2020 and have expressed
2. The figures for the previous period/year have been regrouped /reclassified , wherever necessary.
3. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
4. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015,
5. The Company is operating in single segment, so above results are for single segment only.

Date: 11-11-2020
Place: Ahmedabad

For and on behalf of the Board of Directors
SHUKRA PHARMACEUTICALS LIMITED

M. Patel
Mleshkumar Patel (Director)
DIN: 08316887



CIN : L24231GJ1993PLC019079